<DOC>
	<DOCNO>NCT03048747</DOCNO>
	<brief_summary>The objective study investigate efficacy safety tolvaptan base change serum sodium concentration follow administration tolvaptan oral tablet 7.5 60 mg/day 30 day patient hyponatremia SIADH .</brief_summary>
	<brief_title>A Multicenter Trial Investigate Efficacy Safety Tolvaptan Patients With Hyponatremia SIADH</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hyponatremia</mesh_term>
	<mesh_term>Diabetes Insipidus</mesh_term>
	<mesh_term>Inappropriate ADH Syndrome</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Subjects definite diagnosis SIADH reference `` Diagnostic Treatment Manual Hypersecretion Vasopressin ( SIADH ) , Revised 2011 '' Subjects fluid restriction least 7 consecutive day time informed consent show improvement hyponatremia time screen examination Subjects transient hyponatremia induce drug administration Subjects unable sense thirst difficulty fluid intake Subjects urinary tract obstruction Subjects participate clinical trial within 30 day prior informed consent Subjects serum sodium concentration &lt; 120 mEq/L associate neurologic impairment , include apathy , confusion , seizure</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>